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Prospective study of carotid endarterectomy with
modified polytetrafluoroethylene (ACUSEAL)
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Matthew J. Hofeldt, MD, Stephen M. Hass, MD, and William Perry, Charleston, WVa
Objective: Carotid endarterectomies (CEAs) with standard polytetrafluoroethylene (PTFE) patching have been shown to
have results comparable with those of autogenous vein patching; however, prolonged bleeding through needle holes in
PTFE is a commonly recognized problem. This is the first study of CEA using a new hemostatic modified PTFE patch
(GORE-TEX) analyzing the early and late outcomes.
Methods: Two hundred consecutive CEAs were entered into this protocol. All patients had an immediate postoperative
carotid duplex ultrasound scan that was repeated at 1 month and every 6 to 12 months thereafter. A Kaplan-Meier
analysis was used to estimate the stroke-free survival and the risk of restenosis. The mean follow-up was 21 months
(range, 1 to 48 months).
Results: The perioperative stroke rate was 1.5% (1% ipsilateral and 0.5% contralateral, two minor strokes and one major
stroke) with no perioperative mortality or perioperative carotid thrombosis. The incidence of perioperative transient
ischemic attacks was 3.5% (2.5% ipsilateral and 1% contralateral). The mean hemostasis time after completion of the
patching was 3minutes, in contrast to 14minutes for conventional PTFE (in a previous study). The rates of freedom from
ipsilateral strokes at 1, 2, 3, and 4 years were 99%, 99%, 99%, and 99%, respectively. The cumulative stroke-free survival
rates at 1, 2, 3, and 4 years were 98%, 96%, 93%, and 93%, respectively. The rates of freedom from >70% restenosis at 1,
2, 3, and 4 years were 97%, 97%, 94%, and 94%, respectively.
Conclusions:CEAs with a newmodified PTFE patch are safe, have low perioperative stroke rates, are durable, and have an
acceptable hemostasis time. (J Vasc Surg 2005;41:789-93.)The practice of carotid endarterectomy (CEA) with
patch angioplasty has been shown by several studies to be
more effective than primary closure.1-6 These studies con-
firm that patching decreases the incidence of perioperative
stroke, perioperative carotid thrombosis, and late resteno-
sis. The ideal patch has yet to be identified, with proponents
for both autogenous vein and synthetic grafts reaching no
general consensus. Several studies have shown similar re-
sults for both polytetrafluoroethylene (PTFE) and autoge-
nous vein patching1,2,6-8and also between Dacron and
autogenous vein patching.6,9-11 The advantages of syn-
thetic patches over vein patches include availability, de-
creased operative times, decreased incidence of aneurysmal
dilatation or patch rupture, and avoidance of harvest site
complications.
Some researchers have demonstrated a prolonged he-
mostasis time and excessive bleeding time from needle
holes in PTFE patches.2,7,12,13 Given this concern of ex-
cessive bleeding with PTFE patches, the use of collagen-
impregnated knitted Dacron patches has been advocated.12
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doi:10.1016/j.jvs.2005.02.025(Flagstaff, Arizona) have introduced a new modified PTFE
patch that they claim has a better hemostasis time than
conventional PTFE patching. This is the first study of CEA
using this new hemostatic modified PTFE patch analyzing
the early and late outcomes.
PATIENTS AND METHODS
Two hundred consecutive primary CEAs (187 patients,
13 had bilateral CEAs) were done during a recent 2-year
period (March 2000 to June 2002) using the new hemo-
static modified PTFE (ACUSEAL) GORE-TEX patch
(W. L. Gore & Associates, Inc., Flagstaff, Ariz). The
GORE-TEX ACUSEAL cardiovascular patch uses ad-
vanced fluoropolymer technology, enabling it to “seal”
around penetrating suture and decrease suture line bleed-
ing by as much as 88%. This, combined with improved
suture retention and multidirectional strength, sets the
patch apart from other patches. Increased sealing of suture
holes to minimize bleeding is achieved by including a
middle layer of a proprietary thermoplastic fluoropolymer
with elastic properties. The addition of the dense middle
layer actually increases the suture retention by approxi-
mately 10%. This study was approved by the Institutional
Review Board of Charleston Area Medical Center/Robert
C. Byrd Health Sciences Center of West Virginia Univer-
sity. Before CEA, all patients underwent carotid color
duplex ultrasound scanning and/or magnetic resonance
angiography to determine preoperative stenoses. Various
preoperative risk factors were determined, including hyper-
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ease, and the preoperative use of antiplatelet therapy. Base-
line blood cholesterol and triglyceride levels were also
obtained. The indications for CEA were categorized into
hemispheric transient ischemic attacks (TIAs), amaurosis
fugax, hemispheric strokes, nonhemispheric TIAs, and
asymptomatic significant carotid stenoses.
All procedures were done under general anesthesia with
systemic heparin (5000 to 7000 units) and routine shunt-
ing using carotid Argyle shunts. No protamine was given at
the end of the procedure. Endarterectomies were extended
proximally and distally beyond grossly diseased intima. All
patients were patched using the new modified GORE-TEX
patch (8mmwide and 0.5mm thick) and sutured using 6-0
Prolene sutures. After completion of patching and release
of the carotid clamps, and if no suture bleeding points were
noted, the hemostasis time was recorded as zero. If bleed-
ing points were noted, thrombin-soaked oxidized cellulose
and digital pressure were applied to stop any bleeding
points before closure. Hemostasis was checked after 3
minutes, and, if necessary, in 2-minute increments. Sutures
(6-0 Prolene) were selected in this study because they are
Table I. Demographics/clinical characteristics





Diabetes mellitus 50 (25%)
Smoking 109 (55%)
Hyperlipidemia 111 (55%)
Coronary artery disease 86 (43%)
Preoperative antiplatelet therapy
(aspirin/Plavix) 170 (85%)
Indications for carotid endarterectomy
Hemispheric TIA/amaurosis fugax 87 (43.5%)
Hemispheric stroke 23 (11.5%)
Nonhemispheric symptoms 19 (9.5%)
Asymptomatic 71 (35.5%)
TIA, Transient ischemic attack.
Table II. Perioperative complications
Ipsilateral strokes 2 (1%)
Contralateral strokes 1 (0.5%)
All strokes 3 (1.5%)*
Ipsilateral TIAs 5 (2.5%)
Contralateral TIAs 2 (1%)
All TIAs 7 (3.5%)
Myocardial infarction 1 (0.5%)
Death 0
Hematomas 2 (1%)†
Cranial nerve injury 9 (4.5%)
Superficial wound infection 1 (0.5%)
TIAs, Transient ischemic attacks.
*Strokes: two minor and one major.
†Hematomas: necessitated surgery.commonly used with other patches, and, based on ourprevious observation, when using this patch, the use of this
suture was not associated with an increased bleeding time.
Completion postoperative duplex ultrasound scanning
was doneon all patients. All patientswere started on a regimen
of aspirin (325 mg/d) or Plavix (75 mg/d), if aspirin was
contraindicated, within 24 hours of their surgery.
Surveillance protocol: All patients underwent imme-
diate postoperative color duplex ultrasound scanning that
was repeated at 30 days, 6 months, and every 6 months
thereafter using an ATL HDI 5000 system (Phillips/Ad-
vanced Technology Laboratory, Bellevue, Wash). Report-
able complications were determined in accordance with the
Society of Vascular Surgery Ad Hoc Committee Suggested
Standards for Reports Dealing with Cerebrovascular Dis-
ease.14 Carotid restenosis of 70% was defined by peak
systolic velocities of 150 cm/s on duplex examination
with spectral broadening through systole and an end-
diastolic velocity of  90 cm/s.15
Statistical methods: Life tables were constructed us-
ing SAS 8.01 (Cary, NC) for freedom from ipsilateral
stroke rates, freedom from late restenosis of 70% and
50%, and stroke-free survival.
RESULTS
Two hundred CEAs were done on 187 patients (13
patients had bilateral CEAs). These included 37.5% with
asymptomatic carotid artery stenosis (35% with 70% to
99%, and 2.5% with60% to 70%), 35% with symptomatic
50% to 70% stenosis and 27%with symptomatic 70% to 99%
stenosis (based on duplex ultrasound scan). The mean
follow-up was 21 months (range, 1 to 48 months). Table 1
summarizes the demographic and clinical characteristics of
these patients. As noted in Table 2, the 30-day periopera-
tive stroke rate was 1.5% (1% ipsilateral stroke and 0.5%
contralateral stroke). Overall, there were three strokes in
the series, two minor (with complete recovery in 7 days)
and one major with no perioperative mortality or perioper-
ative carotid thrombosis. Two of these strokes were ipsilat-
eral and noted in the operating room. Both underwent
immediate exploration with intraoperative angiography,
which did not reveal any pathology, and these were
thought to be embolic strokes. These strokes were con-
firmed postoperatively using computed tomography (CT).
The third patient had a contralateral stroke, which was
noted in the recovery room with a normal patent CEA site
on duplex ultrasound examination. This patient was known
to have contralateral carotid artery occlusion.
The incidence of perioperative TIAs was 3.5% (2.5%
ipsilateral and 1% contralateral). Overall, there were five
patients with ipsilateral TIAs; one was noted in the operat-
ing room and immediate exploration with intraoperative
angiography were performed, which was normal with a
normal postoperative CT scan. TIAs in two of the other
four patients were noted in the recovery room and two
within 24 hours after surgery. Two of these ipsilateral TIAs
were similar to preoperative symptoms, and the other three
had a different distribution. Two other patients had con-
tralateral TIAs, one of whom had contralateral occlusion.
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scans and were treated conservatively with antiplatelet ther-
apy.
As noted in Table 2, there were two patients with
significant hematomas (suture holes) that necessitated op-
erative exploration and evacuation. Both patients were on
both aspirin and Plavix before surgery. The mean hemosta-
sis time after completion of patching was 3 minutes (range,
0 to 7 minutes). The mean blood loss was 38 mL.
The rates of freedom from ipsilateral stroke at 1, 2, 3,
and 4 years were 99%, 99%, 99%, and 99% (Fig 1). As noted,
there were no late strokes beyond the two perioperative
ipsilateral strokes in this series. The cumulative ipsilateral
stroke-free survival rates at 1, 2, 3, and 4 years were 98%,
96%, 93%, and 93%, respectively (Fig 2). There were six late
deaths in this series: two secondary to myocardial infarc-
tion, one secondary to congestive heart failure, one second-
ary to pneumonia, one sepsis, and one of unknown cause.
There were five patients with 50% stenosis at the first
Fig 1. Ipsilateral stroke-free rates.
Fig 2. Cumulative ipsilateral stroke-free survival rates.postoperative duplex ultrasound scan or at 30 days, and onepatient with 50% to 60% stenosis at 30 days postopera-
tively. The rates of freedom from70% restenosis at 1, 2, 3,
and 4 years were 97%, 97%, 94%, and 94%, respectively (Fig
3). Overall, there were six patients with 70% restenosis
(two of whom had 50% stenosis 30 days postoperatively
and one had 50% to 60% stenosis at 30 days); four
patients were asymptomatic and two had symptoms that
were associated with a hemispheric TIA. Of the four asymp-
tomatic patients with 70% restenosis, two were observed
and kept on antiplatelet therapy (one refused intervention
and one was too sick to undergo any intervention), one
underwent redo CEA, and one underwent percutaneous
transluminal angioplasty (PTA)/stenting. Of the two pa-
tients with hemispheric TIA symptoms, one underwent
redo CEA and one had PTA/stenting. Figure 4 illustrates
the rates of freedom from 50% restenosis.
DISCUSSION
CEA with patch angioplasty has been shown in several
Fig 3. The rates of freedom from 70% restenosis.
Fig 4. The rates of freedom from 50% restenosis.studies to be superior to primary closure in reducing both
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tion of early thrombosis with patch closure occurs by
changing flow characteristics.17 By widening the artery,
patch angioplasty reduces the incidence of intimal hyper-
plasia.18 However, the ideal patch material has yet to be
identified. Counsell et al5 performed a systematic review of
randomized trials and concluded that the results of autog-
enous saphenous vein and synthetic patching were similar.
Similar observations were noted by Bond et al.19 We re-
ported similar results in a previously published prospective
randomized trial.2 Significant advantages of synthetic
patches include availability of synthetic material, resistance
to aneurysmal dilatation, and elimination of harvesting
complications that can accompany autogenous saphenous
vein use.
When comparing two commonly used synthetic
patches, PTFE (GORE-TEX patch) patch and collagen-
impregnated knitted Dacron patch (Hemashield), PTFE
patching was superior to Hemashield patching in lowering
the incidence of postoperative stroke and late resteno-
sis.20,21 However, some authors have expressed concern
regarding prolonged hemostasis times due to needle hole
bleeding with PTFE patches. Similar observations were
noted in our experience.20 Other investigators have not
seen significant bleeding with PTFE.6,22
In 1999, our institution began using the new modified
PTFE patch (GORE-TEX, W.L. Gore & Associates) in
hopes of reducing needle hole bleeding. This current study
prospectively evaluated the mean hemostasis time, periop-
erative neurologic events, and restenosis rates using the
ACUSEAL patch. When these results were compared with
the standard PTFE patching used in our previous prospec-
tive, randomized trials, the mean hemostasis time was
significantly lower with the modified PTFE patch. The
modified PTFE patch achieved hemostasis at a mean of 3
minutes versus 14 minutes for the conventional PTFE
patch.20 It should be noted that we used 6-0 Prolene
sutures in this study, in contrast to PTFE sutures (TT-9
needle and CV-6 sutures) in the previous study.
Jackson et al23 conducted a randomized study of the
hemostatic efficacy of fibrin sealant (human) on expanded
PTFE carotid patch angioplasty. They evaluated the effi-
cacy of solvent detergent-treated fibrin sealant (human
[FSH]) for controlling anastomotic bleeding from ex-
panded PTFE patch angioplasty during CEA, and FSHwas
compared with thrombin-soaked gelatin sponge (Gelfoam
[TSG]). They concluded that the time to hemostasis was
the same for both groups (TSG, 16.5  16.5 minutes;
FSH, 16.6  14 minutes; P  .97).
Joseph et al24 also conducted a randomized, controlled
trial to evaluate the efficacy of TachoComb H patches
(Nycomed, Linz, Austria) in controlling PTFE suture hole
bleeding. Patients undergoing femoral anastomosis and
femoral or carotid patch angioplasty with PTFE grafts were
prospectively randomized to TachoComb H patches or
standard compression with surgical swabs. The Tacho-
Comb H patch consists of an equine collagen sponge
coated with the hemostatic factors fibrinogen and throm-bin. It is a ready-to-use and absorbable hemostatic dress-
ing. Twenty-four patients were randomized (12 patients in
each treatment group). The median time to hemostasis was
300 seconds in patients treated with TachoComb H and
660 seconds in the control group (P  .0134).
The perioperative ipsilateral stroke rate with the mod-
ified patch was comparable with that of the conventional
PTFE patch (1% vs 0%). Finally, the modified patch
achieved a 94% freedom from 70% restenosis rate at 36
months, which was similar to that of the conventional
PTFE patch. None of the 200 patients developed a patch
infection during follow-up, which has been a concern ex-
pressed by those favoring autogenous material.
The data presented in this study continue to show
encouraging results with PTFE-based patches. The modi-
fied PTFE patch has a short hemostasis time, excellent
perioperative results, and minimal incidence of restenosis.
In contrast to our results, O’Hara et al25 and others have
shown good results with the Dacron patch, citing lower
rates of perioperative neurologic events similar to those
using autogenous saphenous vein patches. Archie3 re-
ported the results of a nonrandomized series of 1360 CEAs
over 15 years, comparing three types of patches (saphenous
vein, Dacron, and PTFE). He concluded that the results of
CEAs patched with saphenous veins were superior to those
of CEAs patched with synthetic materials, particularly Da-
cron, in regards to stroke and restenosis rates. He also
reported the results of a meta-analysis of three studies that
used both saphenous vein andDacron patch reconstruction
during CEA and three other studies that used both saphe-
nous vein and PTFE patch reconstruction. The periopera-
tive stroke rate for Dacron patching was 3% (598 CEAs)
versus 1% for vein patching (675 CEAs, P  .025). Simi-
larly, the perioperative stroke rate for PTFE patching was
2.1% (331CEAs) versus 0.3% for vein patching (363CEAs,
P  .056).
In conclusion, the results of CEAs with the new mod-
ified PTFE patches are encouraging, with low perioperative
stroke rates and restenosis rates with acceptable hemostasis
times. Additional studies with longer follow-up are needed.
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